益生菌-药物结合物实现同步的特定部位益生菌定居和按需释放治疗性结肠炎及其并发症的药物
Linzhou Yin1, Shuwen Han2,3,4, Jiang Xiaowen1
1School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
新的益生菌药物结合剂为性结肠炎 (UC) 提供了向治疗. 这些结合物直接将益生菌和抗炎药物输送到炎症的结肠部位,提高疗效并减少副作用.
科学领域:
- 胃肠病学和生物医学工程
- 药物输送系统
- 微生物学
背景情况:
- 性结肠炎 (UC) 治疗面临当前益生菌疗法的挑战,原因是局部特定殖民和有限的配送.
- 现有的表面修饰益生菌缺乏在病变部位的选择性定居,并且难以与其他治疗药物一起提供.
研究的目的:
- 在UC治疗中开发可触发的新型益生菌药物合物,用于同步的,特定地点的殖民和按需的药物释放.
- 通过有针对性的治疗来提高性结肠炎及其并发症的疗效.
主要方法:
- 工程 * Escherichia coli * Nissle 1917 与酸-铁酸内层结合,用于粘附和对ROS敏感的基脂外层.
- 在UC小鼠模型中口服,利用炎症结肠中的高反应性氧物种 (ROS) 水平来触发药物和益生菌的释放.
主要成果:
- 在炎症的结肠病变部位同步释放抗炎和粘性益生菌.
- 在UC和相关并发症的小鼠模型中显示出显著的治疗和预防效果.
- 通过有针对性的输送实现了炎症抑制和持续的肠道微生物群调节.
结论:
- 开发的益生菌药物合物在治疗UC等胃肠道疾病方面具有显著的转化潜力.
- 这种方法可以通过确保特定地点的益生菌和药物提供联合治疗策略.
- 这种可触发性释放机制为治疗炎症性肠道疾病提供了一个有前途的新途径.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
05:45Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
